Intradermal hepatitis B vaccination in those not responsive to intramuscular vaccination

Harefuah

Volumn 134, Issue 6, 1998, Pages

  Bauer, Hanna ^a   Potasman, Israel ^a   Pick, Neora ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; EMPLOYEE; HEALTH CARE PERSONNEL; HEPATITIS B; HOSPITAL PERSONNEL; HUMAN; IMMUNOGENICITY; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; VACCINATION;

ADULT; CARRIER STATE; FEMALE; HEALTH PERSONNEL; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED;

EID: 0032521618     PISSN: 00177768     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Centers for disease control. Changing patterns of groups at high risk for hepatitis B in the United States. MMWR, 1988; 37: 429-432.
2. Department of labor/Department of Health and Human Services. Protection against occupational exposure to hepatitis B virus and the human immunodeficiency virus. Washington DC, US government printing office, 1987, 1-14.
3. CDCP, Hepatitis surveillance report No. 52. Atlanta: US Department of Health and Human Services, Health Service, 1989.
4. Egoz N, Naggan L, Feingold A & Bar Shany S, Prevalence of Hepatitis B antigen among army inductees. Isr J Med Sci, 1975; 11: 777-80.
5. Sandler SG, Nath N & Biger Y, Seroepidemiology of hepatitis B virus in Israel. Results of a pilot study in Jerusalem. Am J Epidemiol, 1977; 106: 76-82.
6. Hamilton JD, Hepatitis B virus vaccine: an analysis of its potential use in medical workers. JAMA, 1983; 250: 214-50.
7. Baker CH & Brennan JM, Keeping health-care workers healthy: lecal aspects of hepatitis B immunization programs. N Engl J Med, 1984; 311: 684-8.
8. Donchin M & Shouval D, Occupational and non-occupational hepatitis B virus infection among hospital employees in Jerusalem: a basis for immunization strategy. Br J Ind Med, 1992; 49: 620-5.
9. Houston SH, Sinnott JT & Shea JP, Infectious Disease Aspects of Employee Health. A brief overview. In: Reese RE, Betts KF(eds). A Practical Approach to Infectious Diseases. Little, Brown, 1996, p 1406, New York.
10. Inactivated hepatitis B virus vaccine: recommendations of Immunization Practices Advisory Committee. MMWR, 1982; 31: 317-28.
11. Wood RC, MacDonald KL, White KE & al, Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health-care workers. JAMA, 1993; 270: 2935-9.
12. Roome AJ, Walsh SJ, Cartter ML & Hadler JL, Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA, 1993; 270: 2931-4.
13. Weissman JY, Tsuchiyose MM, Tong MJ & al, Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA, 1988; 260: 1734-8.
14. King JW, Taylor EM, Crow SD & al, Comparison of the immunogenicity of hepatitis B vaccine administered intradermally and intramuscularly. Rev Infect Dis, 1990; 12: 1035-43.
15. Bertino JS, Tirrell P, Greenberg RN & al, A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particels for revaccination of healthy adult nonresponders. J Infect Dis, 1997; 175: 678-81.
16. Hourvitz A, Mosseri R, Solomon A & al, Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing pre-S1 antigents: a preliminary report. J Viral Hepatol, 1996; 3: 37-42.
17. Michel ML, DNA mediated immunization: prospects for hepatitis B vaccination. Res Virol, 1995; 146: 261-5.
18. Davis HL, McCluskie MJ, Gerin JL & Purcell RH, DNA vaccines for hepatitis B: evidence for immunogenicity in chimpanzees and comparison with orther vaccines. Proc Natl Acad Sci (USA) 1996; 93: 7213-8.
19. Struve J, Aronsson B, Frenning B & al, Intramuscular versus intradermal administration of a recombinant hepatitis B vaccine: a comparison of response rates and analysis of factors influencing the antibody response. Scand J Infect Dis, 1992; 24: 423-9.
20. Levitz RE, Cooper BW & Regan HC, Immunization with high-dose intradermal recombinant hepatitis B vaccine in healthcare workers who failed to respond to intramuscular vaccination. Infect Control Hosp Epidemiol, 1995; 16: 88-91.
21. Harpaz R, Von Seidlein L, Averho FM & al, Transmission of Hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med, 1996; 334: 549-54.
22. The Incident Investigation Team. Transmission of hepatitis B to patients from four infected surgeons without hepatitis Be antigen. N Engl J Med, 1996; 336: 178-84.
23. Hatae K, Kimura A, Okubo R & al, Genetic control of nonresponsiveness to hepatitis B virus vaccine by an extended HLA haplotype. Eur J Immunol, 1992; 22: 1899-905.
24. Watanabe H, Matsushita S, Kamikawaji N & al, Immune suppression gene on HLA-Bw54-DRw53 haplotype controls nonresponsiveness in humans to hepatitis B surface antigen via CD8+ suppressor T cells. Hum Immunol, 1988; 22: 9-17.
25. Hsu HY, Chang MH, Hsieh RP & al, Association of HLA-DR14k-DR52 with low responsiveness to hepatitis B vaccine in Chinese residents in Taiwan. Vaccine, 1993; 11: 1437-40.
26. Vingerhoets J, Goilav C, Vanham G & al, Non-response to a recombinant pre-S2 containing hepatitis B vaccine: association with the HLA system. Ann Soc Belg Med Trop, 1995; 75: 125-9.
27. Elavia AJ, Marfatia SP & Banker DD, Immunization of hospital personnel with low-dose intradermal hepatitis B vaccine. Vaccine, 1994; 12: 87-90.
28. McKee CM, Duke P, McEvoy MB & Kelsey MC, Effectiveness of intradermal hepatitis B immunization of hospital staff. Int J STD AIDS, 1990; 1: 32-4.
29. Tompson SC, Darlington R, Tallent D & al, Effectiveness of low-dose intradermal hepatitis B vaccination. Five years' experience of primary vaccination. Med J Austr, 1993; 158: 372-5.
30. Shouval D, Ilan Y, Adler R & al, Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine, 1994; 12: 1453-9.
31. Raz R, Dagan R, Gallil A & al, Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens in children. Vaccine, 1996; 14: 207-11.
32. Immunization Practices Advisory Comittee. Inadequate immune response among public safety workers receiving intradermal vaccination against hepatitis B, United States, 1990-1991. MMWR, 1991; 40: 569-72.
33. Bryan JP, Sjogren M, Iqbal M & al, Comparative trial of low-dose, intradermal, recombinant, and plasma-derived hepatitis B vaccine. J Infect Dis, 1990; 162: 789-93.
34. Gonzales ML, Usandizaga M, Alomar P & al, Intradermal and intramuscular route for vaccination against hepatitis B. Vaccine, 1990; 8: 402-5.
35. Horowitz MM, Ershler WB, McKinney WP & Battiola RJ, Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine. Ann Intern Med, 1988; 108: 185-9.
36. Zuckerman AJ, Appraisal of intradermal immunization against hepatitis B. Lancet, 1987; 1: 435-6.
37. Lancaster D, Elam S & Kaiser AB, Immunogenicity of the intradermal route of hepatitis B vaccination with the use of recombinant hepatitis B vaccine. Am J Infect Control, 1989; 17: 126-9.
38. Zoulek G, Lorbeer B, Jilg W & Friedrich D, Persistence of anti-HBs after intradermal inoculation of reduced doses of hepatitis B vaccine. Lancet, 1987; 2: 983-984.
39. Goldwater PN, Hypersensitivity to intradermal hepatitis B vaccine. Lancet, 1984; 2: 1156.
40. Nottebart HC, Current legal issues. In: Wenzel RP (ed). Prevention and control of nosocomial infections. Williams, 1987, p 45, Baltimore.